Novel peptide inhibitors for Grb2 SH2 domain and their detection by surface plasmon resonance
F-D T Lung1, J-Y Tsai, S-Y Wei
1Department of Nutrition, China Medical College, Taichung 404, Taiwan. fdlung@mail.cmc.edu.tw
Abstract:
One of the critical intracellular signal transduction pathways involves the binding of the Grb2 SH2 domain to the phosphotyrosine (pTyr) motifs on growth factor receptors, such as epidermal growth factor receptor (EGFR) and erbB2, leading to downstream activation of the oncogenic Ras signaling pathway. Therefore, the Grb2 SH2 domain has been chosen as our target for the development of potential anticancer agents. As a continuation of our earlier work, herein we report the design and synthesis of new peptide analogs, and their inhibitory effect on the Grb2 SH2 domain using surface plasmon resonance (SPR) technology. These novel agents do not contain phosphotyrosine or phosphotyrosine mimics. Binding interactions between these peptides and the Grb2 SH2 domain were measured and analyzed using a BIAcore X instrument, which provides detailed information on the real-time detection of the binding interaction. The results of this study should provide important information for the further development of peptides or peptidomimetics with high affinity for the Grb2 SH2 domain.
Insights
Researchers developed novel peptide analogs targeting the Grb2 SH2 domain, a key player in cancer signaling. These agents, without phosphotyrosine mimics, show potential for developing new anticancer therapies by inhibiting Grb2 SH2 domain interactions.
Area of Science:
- Molecular Biology
- Biochemistry
- Pharmacology
Background:
- Intracellular signal transduction pathways are crucial in cellular processes.
- The Grb2 SH2 domain binds to phosphotyrosine motifs on growth factor receptors, activating the oncogenic Ras pathway.
- Targeting the Grb2 SH2 domain offers a strategy for developing anticancer agents.
Purpose of the Study:
- To design and synthesize new peptide analogs targeting the Grb2 SH2 domain.
- To evaluate the inhibitory effects of these novel agents on Grb2 SH2 domain interactions.
- To provide insights for developing high-affinity peptides or peptidomimetics against the Grb2 SH2 domain.
Main Methods:
- Design and synthesis of novel peptide analogs.
- Surface Plasmon Resonance (SPR) technology using a BIAcore X instrument for real-time binding analysis.
- Measurement and analysis of binding interactions between peptides and the Grb2 SH2 domain.
Main Results:
- Novel peptide analogs were synthesized and evaluated for their inhibitory effects.
- Binding interactions with the Grb2 SH2 domain were quantitatively measured using SPR.
- The study provides real-time data on the binding kinetics and affinity of the novel agents.
Conclusions:
- The developed peptide analogs represent potential therapeutic agents targeting the Grb2 SH2 domain.
- These agents do not rely on phosphotyrosine or its mimics for binding.
- The findings contribute to the development of novel anticancer strategies focused on inhibiting critical signaling pathways.
